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human health and validated drug targets are urgently required. To define a protein’s 
function	in	vivo	and	thereby	validate	it	as	a	drug	target,	highly	specific	tools	are	re-
quired	that	modify	protein	function	with	minimal	cross-reactivity.	While	modern	ge-
netic	approaches	often	offer	 the	desired	 level	of	 target	specificity,	applying	 these	
techniques is frequently challenging—particularly in the most dangerous malaria 
parasite,	Plasmodium falciparum. Our hypothesis is that such challenges can be ad-
dressed by incorporating mutant proteins within oligomeric protein complexes of the 
target	organism	in	vivo.	In	this	manuscript,	we	provide	data	to	support	our	hypothe-
sis by demonstrating that recombinant expression of mutant proteins within P. falci‐
parum leverages the native protein oligomeric state to influence protein function in 
vivo,	thereby	providing	a	rapid	validation	of	potential	drug	targets.	Our	data	show	
that interference with aspartate metabolism in vivo leads to a significant hindrance in 
parasite survival and strongly suggest that enzymes integral to aspartate metabolism 
are promising targets for the discovery of novel antimalarials.
K E Y W O R D S
drug	target	validation,	oligomeric	state,	phenotypic	mapping,	Plasmodium falciparum,	
structural biology
2 of 14  |     BATISTA eT Al.
1  | INTRODUC TION
The parasite Plasmodium falciparum is responsible for the most le-
thal	form	of	human	malaria	(World	Health	Organization,	2017).	The	






discovering targeting P. falciparum,	 the	 validation	 of	 these	meta-
bolic steps remains challenging due to limitations of applicability 
of probe techniques in P. falciparum and dependence upon reverse 
genetics	 (Meissner	 et	 al.,	 2016).	 This	 highlights	 the	 necessity	 of	
development of novel validation techniques capable of simplify-
ing the validation of potential targets in P. falciparum—as well as 
other parasitic organisms. The examination of interaction surfaces 
between subunits of oligomeric proteins might offer a relatively 
straightforward	alternative	to	this	process	(Meissner	et	al.,	2016).
Protein	oligomerization,	 the	 assembly	of	 two	or	more	 copies	
of	 a	 single	protein	 into	one	object,	 is	 a	 feature	 shared	by	 all	 or-
ganisms and is present in more than 60% of all protein structures 
currently	available	within	the	Protein	Data	Bank	(PDB;	Hashimoto,	
Nishi,	 Bryant,	 &	 Panchenko,	 2011).	 The	 biological	 importance,	
physicochemical	 properties,	 and	 evolutionary	 aspects	 of	 pro-
tein	 oligomerization	have	been	 recently	 summarized	 (Hashimoto	
&	 Panchenko,	 2010;	 Hashimoto	 et	 al.,	 2011;	 Nishi,	 Hashimoto,	
Madej,	 &	 Panchenko,	 2013).	 Furthermore,	 lower	 degree	 of	 evo-





esized that the introduction of functionally incompetent forms of 
an enzyme into the native oligomeric assembly could be exploited 
in	 the	 analysis	 of	 biochemical	 pathways	 in	 vivo,	 particularly	 in	
cases	where	 standard	 techniques	 (e.g.,	RNAi/knock	 in/out)	 have	
a low success rate.
The aspartate metabolism pathway within P. falciparum contains 
a number of oligomeric enzymes making it an ideal system to test 
our	hypothesis	that	oligomeric	self-assembly	can	be	used	to	modu-
late	in	vivo	behavior.	Aspartate	interconversion	is	essential	for	ni-
trogen metabolism of all organisms. In Plasmodium	species,	 it	was	
also proposed to play a key role in de novo pyrimidine biosynthesis 
as	 well	 as	 energy	metabolism	 (Wrenger	 et	 al.,	 2011).	 Plasmodial	
aspartate	aminotransferase	 (PfAspAT)	 and	malate	dehydrogenase	
(PfMDH)	 catalyzes	 the	 reversible	 reaction	 from	aspartate	+	2-ox-
oglutarate	 to	 oxaloacetate	+	glutamate	 and	 malate	+	NAD	 to	 ox-
aloacetate	+	NADH,	respectively.	The	crystal	structure	of	PfAspAT	
has	 been	 previously	 solved	 (Wrenger	 et	 al.,	 2011).	 As	 reported,	
PfAspAT	 is	 a	 homo-dimer	 with	 a	 molecular	 weight	 of	 48.42	kDa	
per	monomer	(Wrenger	et	al.,	2011).	Similarly	to	the	previously	de-
scribed	AspAT	of	E. coli (Jäger,	Moser,	Sauder,	&	Jansonius,	1994), 
each	subunit	consists	of	 three	major	domains:	an	N-terminal	arm	
(residues	 1–14),	 a	 large	 coenzyme-binding	 domain	 (residues	 36–
321)	and	a	smaller	domain	(residues	15–36	and	322–404).	The	N-
terminal	arm	domain	(residues	1–14)	distal	from	either	active	site	is	
thought to stabilize the PfAspAT	dimer	and	is	necessary	for	activ-
ity,	as	truncated	species	lacking	the	N-terminal	extension	showed	
significantly reduced activity while retaining dimeric structure 
(Wrenger	et	al.,	2011).	The	two	active	sites	of	PfAspAT	are	formed	
in a cleft between the big and small domains near the oligomeric 
interface and each active site pocket is composed of residues con-
tributed from both subunits. Previous experiments where PfAspAT	
was selectively inhibited in vitro using a polypeptide chain consist-
ing	of	first	50	PfAspAT	amino	acids	(Wrenger	et	al.,	2011)	confirm	
the hypothesis that oligomeric interfaces show significantly higher 
sequence divergence amongst homologs and thus offer potential in 
specific interference with a target protein.
The structure PfMDH	has	also	been	recently	solved,	and	we	have	
provided an insight into the role of oligomeric assembly in the reg-
ulation of PfMDH	activity	(Lunev	et	al.,	2018).	PfMDH	possesses	a	
tetrameric conformation where each monomer is comprised of 326 
residues	and	is	composed	of	two	major	domains:	an	N-terminal	co-
factor-binding	 domain	 containing	 a	 parallel	 structure	 of	 six	 beta-
sheets	 (Rossmann-fold)	 and	 C-terminal	 substrate-binding	 domain.	
Our previous results suggested that a correctly formed tetrameric 













tive activity. These data demonstrate that recombinant mutants can 
be	used	as	specific	modifiers	of	wild-type	PfMDH	activity	in	vitro,	of-
fering	the	potential	to	validate	it	as	a	drug	target,	without	recourse	to	
complex genetics or initial tool compounds that may display signifi-
cant	off-target	effects	(Lunev	et	al.,	2018).	However,	neither	PfAspAT	
nor PfMDH	has	as	yet	been	validated	as	a	drug	target	in	vivo.
In	 this	 study,	 structural	 information	 of	 the	 enzymes	 PfMDH	
and PfAspAT	was	used	to	generate	mutants	for	use	in	in	vivo	pro-
tein interference experiments following two different approaches. 
In	 the	 first	 approach,	we	designed	mutants	 that	would	 incorpo-





activity of the target enzymes was determined within the lysate 
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of	transgenic	parasites,	suggesting	successful	incorporation	of	the	
mutants within the targeted assemblies. The resulting data clearly 
indicate a significant dependence of the parasite on functional 
aspartate	metabolism.	Our	data	also	provide	proof-of-principle	for	
protein	interference	assay	(PIA)	as	a	general	approach	to	the	use	
of oligomeric assemblies to obtain functional data in vivo.
2  | RESULTS
2.1 | The oligomeric interface of PfAspAT shows 
higher sequence diversity than its active site
BLAST	(Altschul,	Gish,	Miller,	Myers,	&	Lipman,	1990)	analysis	of	
the close homologs of PfAspAT	 showed	overall	 38.7%	 sequence	
conservation,	 while	 the	 residues	 comprising	 the	 active	 site	 of	
PfAspAT	 showed	 a	 sequence	 conservation	 of	 100%	 (Table	 1;	
Figure	1).	PISA (Krissinel	&	Henrick,	 2007)	 analysis	 of	 the	 struc-
tural assembly of PfAspAT	 identified	 98	 residues	 involved	 in	
the	 inter-oligomeric	 contact,	 showing	 sequence	 conservation	 of	
34.7%	(Table	1),	where	10.2%	accounts	for	the	active	site	residues.	
As	 previously	 mentioned	 (Wrenger	 et	 al.,	 2011),	 the	 N-terminal	




2.2 | Point mutations of the key active site residues 
abolish catalytic activity of PfAspAT in vitro while not 
disturbing the dimerization and overall fold
Based on the crystal structure of PfAspAT	(3K7Y;	Wrenger	et	al.,	2011),	
point mutations were designed in order to interfere with the catalytic 
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F I G U R E  2   Sequence alignment of PfAspAT	against	the	closest	homologs
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activity of PfAspAT.	Arginine	257	and	Tyrosine	68	of	a	single	PfAspAT	





residues would significantly affect the catalytic activity of PfAspAT.	
Furthermore,	as	Tyr68	and	Arg257	belong	 to	different	 subunits,	 the	
double	mutation	Y68A/R257A	in	a	single	monomer	would	affect	both	
active sites of the dimer. The PfAspAT-Y68A/R257A	mutant	was	 re-
combinantly	expressed	and	purified.	Static	light	scattering	(SLS)	meas-
urements confirmed that the introduction of both active site mutations 
did	not	impact	the	oligomeric	assembly,	as	both	wild	type	and	mutant	
versions	had	a	molecular	weight	of	approx.	94	kDa,	consistent	with	a	
dimeric	 assembly	 (Figure	 4).	 The	 specific	 activity	 of	 the	 double	mu-
tant of PfAspAT-Y68A/R257A	was	measured,	showing	loss	of	activity	





2.3 | Inactivated PfAspAT mutant copies can 
be incorporated into the native assembly during 
recombinant expression in E. coli
Assuming	 that	 double	 mutation	 Y68A/R257A	 affects	 both	 active	
sites of one PfAspAT	dimer,	we	further	hypothesized	that	formation	
of PfAspAT	wild-type/mutant	chimera	would	also	affect	both	active	
sites and result in a significantly less active enzyme.
The PfAspAT-Y68A/R257A	gene	was	sub-cloned	into	the	pBM1	
vector	 using	 sequence-specific	 primers	 (Appendix	 1)	 and	 the	
resulting	 pBM1-PfAspAT-Y68A/R257A	 plasmid	 encoded	 the	 full-
length PfAspAT	gene	with	both	mutations	and	a	His6-tag	 fused	at	
the	 C-terminus.	 The	wild-type	 PfAspAT	with	 C-terminal	 Strep-tag	
was	 expressed	 according	 to	 a	 previously	 reported	 protocol	 (Jain,	
Jordanova,	Müller,	Wrenger,	&	Groves,	2010).
Recombinant	 co-expression	 of	 both	wild-type	PfAspAT	 (Strep-
tagged)	 and	 PfAspAT-Y68A/R257A	 (His6-tagged)	 mutant	 was	 per-
formed in E. coli	and	the	lysate	from	the	co-expression	was	purified	
by	Strep	tactin-affinity	and	Ni-affinity	chromatography	(Figure	5a).	
A	western	 blot	 analysis	 of	 both	 eluates	 clearly	 demonstrated	 the	
presence	of	His6-tagged	double	PfAspAT	mutant	in	a	Strep-purified	
sample	 (Figure	5b,	 lane	2)	as	well	as	the	Strep-tagged	wild	type	 in	
the	His6-purified	sample	(Figure	5b,	lane	3).	These	results	were	inter-
preted as the formation of a dimer consisting of both wild type and 
mutant	species	of	2.4	PfAspAT	during	co-expression.
Further	 activity	 measurements	 indicated	 that	 Strep-purified	







can be introduced into the native PfAspAT	dimeric	assembly	through	
co-expression	resulting	in	an	inactivated	chimeric	protein.
2.4 | Introduction of PfAspAT and PfMDH mutants 
results in a significant reduction in parasitaemia in 
aspartate‐limited culture media
The cytosolic localization of PfAspAT	 within	 the	 parasite	 has	
previously	 been	 reported	 (Wrenger	 et	 al.,	 2011).	 Similarly,	 the	
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cytosolic localization of PfMDH	has	been	visualized	by	expression	of	
a PfMDH-GFP	chimera	(Figure	6).	In	order	to	assess	the	effect	of	the	
presence of mutated PfAspAT	and	PfMDH	in	vivo,	expression	plas-
mids for PfAspAT-Y68A/R257A	 and	PfMDH-V190W	were	 created	
for transfection into P. falciparum.	As	the	expression	from	the	intro-
duced plasmids is likely to result in an excess of the mutant protein 






a	 dimeric	 assembly	 with	 no	 activity.	 Thus,	 the	 overexpression	 of	
PfMDH-V190W	 or	 PfAspAT-Y68A/R257A	 in	 vivo	 could	 be	 antici-
pated to result in inhibition of PfMDH	or	PfAspAT	activity	with	lit-
tle	or	no	off-target	effects.	As	one	of	the	major	functions	of	these	







further demonstration that P. falciparum possesses a fully functional 
aspartate biosynthetic pathway. The introduction of PfAspAT-Y68A/
R257A	or	PfMDH-V190W	alone	resulted	in	no	detectable	effects	on	
blood-stage	parasite	growth	 in	aspartate	 rich	or	aspartate	 limiting	
media	 (Figure	7a,b).	However,	 this	demonstrates	 that	 there	are	no	
significant negative effects of introducing either the plasmids or the 
mutant proteins in vivo in terms of effects on parasite growth. While 
no effect is observed when both mutant proteins are introduced si-
multaneously	in	aspartate-rich	media,	a	significant	effect	(an	almost	
100-fold	reduction	in	parasitaemia)	is	seen	on	parasite	proliferation	
in	 aspartate-limiting	 cultures	 (Figure	 7c).	 As	 neither	mutant	 alone	
showed	 any	 negative	 effect	 on	 parasite	 growth	 in	 aspartate-lim-
ited	media,	we	 interpret	 this	 data	 to	mean	 that	we	 have	 success-
fully inhibited both PfMDH	and	PfAspAT	in	vivo.	As	indicated	above,	
our approach is unlikely to result in complete inhibition of either 
PfAspAT	or	PfMDH	so	the	residual	growth	seen	in	the	mutant-inhib-
ited cultures is most probably due to residual activity of uninhibited 
PfAspAT	and	PfMDH.	Subsequently,	to	prove	that	the	double-trans-
fect cell line expresses the transgenic proteins the overexpression of 
both	transcripts	was	determined	by	qRT-PCR.	Compared	to	the	wild-




2.5 | Activity measurements of 
PfMDH and PfAspAT in parasite lysates confirm the 
formation of the heterocomplexes
In order to confirm the activity profile of both enzymes in the re-
spective	transfected	parasites,	we	performed	specific	activity	assays	
using	parasite	extracts	(Figure	10).	As	expected,	proteins	extracted	





but were also functional. The proteins extracted from parasites 
transfected with the mutant gene PfMDH-V190W	 showed	 a	mild	
reduction	in	specific	activity	(68.78	±	8.65	mU/mg)	compared	to	the	
control	(76.06	±	0.68	mU/mg,	Figure	10a).	However,	this	difference	
was not statistically significant. The effect of the transfection with 
PfAspAT-Y68A/R257A	mutant	 was	 more	 pronounced	 (3.32	±	0.06	
F I G U R E  4   (a)	Size-exclusion	chromatograms	of	PfAspAT-WT	as	
well	as	its	active	site	mutants.	All	samples	were	loaded	onto	S75	
SEC column and eluted as single peaks with elution volumes of 
60–62	ml.	(b)	SLS	experiments	of	PfAspAT-WT	and	simple	mutants,	
PfAspAT-Y68A	and	PfAspAT-R257A
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compared	to	the	control	of	5.03	±	0.46	mU/mg,	Figure	10b).	These	
results	confirm	that	the	presence	of	mutant	or	extra	wild-type	cop-
ies of proteins within the parasite could form complexes with the 
native	enzymes	and,	as	a	consequence,	decrease	or	increase	the	ac-
tivity of the targeted oligomers.
3  | DISCUSSION
In order to show the use of oligomeric surfaces in establishing pro-
tein	interference	studies	in	an	in	vivo	setting,	we	have	characterized	
the assembly surfaces of two plasmodial enzymes: aspartate ami-
notransferase	(PfAspAT)	and	malate	dehydrogenase	(PfMDH),	that	
are	both	localized	in	the	cytosol	of	the	parasite	(Figure	6a;	Wrenger	
et	al.,	2011).	 In	order	 to	validate	 the	druggability	of	 the	 targeted	
malate-aspartate	 pathway,	 structure-based	 mutagenesis	 experi-
ments of the two involved genes were performed. We have recently 
demonstrated that a surface mutation in PfMDH,	where	valine	190	













F I G U R E  6   (a)	Cytosolic	localization	
of PfMDH	visualized	inside	the	parasite	
by expression of a PfMDH-GFP	chimera.	
(b)	Protein	expression	of	the	transgenic	
cell line PfMDH-GFP	chimera	verified	via 
western	blot,	the	chimera	has	a	molecular	
weight	of	61.5	kDa
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of	 the	 tetramer	 into	a	pair	of	dimers	but	 it	 also	made	 the	 re-for-
mation of the tetramer highly unlikely due to the introduction of 
molecular clashes. It was also previously reported that the mutated 
















expressed in P. falciparum	blood-stage	cultures,	and	we	have	demon-
strated that the hypothesized PfAspAT	chimeras	are	formed	inside	the	
parasite	in	vivo,	through	measurement	of	PfAspAT	activity	in	the	lysate	
of	transgenic	parasites.	While	no	effect	is	seen	in	aspartate-rich	media,	
the	 introduction	of	both	mutant	proteins	 in	 aspartate-limited	media	
results	 in	a	clear	phenotype	(Figure	7),	without	recourse	to	complex	
genetic manipulations. We have termed this approach the oligomeric 
protein	interference	assay	(PIA;	Meissner	et	al.,	2016).
Our data show that oligomeric surfaces can be used to specifi-
cally inhibit protein activity in vivo, especially in cases when oppor-
tunities for genetic manipulation are limited. The introduction of 
PfAspAT-Y68A/R257A	or	PfMDH-V190W	alone	did	not	result	in	any	
significant	 effect	 on	 parasite	 proliferation	 in	 blood-stage	 cultures	
(Figure	7a,b).	Nonetheless,	we	believe	 that	 these	 findings	demon-
strate that the expression of mutant proteins in cultured parasites 
has overall no negative effects on parasite growth. This also indi-
cates	 that,	while	 the	 expression	 levels	 of	 the	mutant	 proteins	 are	
significantly	higher	(up	to	fourfold)	than	their	endogenous	counter-
parts,	they	are	likely	not	overexpressed	at	a	level	that	would	induce	
metabolic stress on P. falciparum through depletion of amino acids. 
As	the	mutant	proteins	introduced	are	designed	and	demonstrated	
to	 be	 inactive,	 it	 is	 also	 highly	 unlikely	 that	 we	 have	 significantly	
altered	 the	metabolic	balance	within	 the	parasite.	 In	 addition,	 our	
experiments	 utilized	well-characterized	 expression	 plasmids	 to	 in-
troduce the mutant proteins and numerous previous publications 
have not reported significant effects of these plasmids on parasite 
growth	(Butzloff,	2013;	Knöckel	et	al.,	2012;	Meissner	et	al.,	2016;	
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Müller	et	al.,	2009).	The	lack	of	negative	effect	on	the	proliferation	
of culture parasites is supported by the measurements of specific 
activity of both enzymes in lysates of parasites transfected with the 
mutant	genes,	which	show	that	these	parasites	retain	a	partial	activ-
ity	of	both	enzymes	(Figure	10a,b).	Additionally,	continuous	expres-
sion of the inserted mutant reduces the risk of possible degradation 
of the mutant protein by cellular proteases before it reaches the in-
tended	 targets.	 Further,	 our	mutations	were	 designed	 to	 result	 in	
inactive	proteins	(confirmed	by	our	in	vitro	activity	assays	(Lunev	et	
al.,	2018),	Figure	3c).	In	fact,	the	activity	assay	in	lysates	of	parasites	
supports not only the hypothesis that the introduction of mutated 
proteins	will	cause	a	decrease	in	the	activity,	but	also	indicates	that	
the	formation	of	heterocomplexes	occurs	in	vivo,	thereby	influenc-
ing the function of the native protein.
Finally,	 in	 contrast	 to	 current	 small	 molecule	 inhibition	 ap-
proaches,	no	limitations	regarding	drug	or	compound	delivery	to	the	
cytosol are encountered as the mutant proteins are expressed di-
rectly	within	the	parasite.	Based	on	this	analysis,	we	believe	that	the	
introduction of inactive proteins specific for oligomeric targets rep-
resents a minimally perturbing method to specifically inhibit meta-
bolic pathways of interest in the human malaria parasite P. falciparum 
that	will	have	a	minimal	off-target	effect,	and,	in	this	manner,	offers	a	
possible tool to be used in the validation of target candidates.
While the insertion of the individual mutations of PfMDH	 or	
PfAspAT	results	in	no	negative	effect	on	parasitemia,	the	transfec-
tion of parasites with both plasmids results in a significant reduction 
in	parasite	proliferation	in	aspartate-limited	media	(Figure	7c).	This	is	
a clear change in phenotypic behavior that has been generated with-
out recourse to complex genetic approaches. These data strongly 
suggest that while the correct function of either PfMDH	or	PfAspAT	
is	sufficient	to	support	parasite	proliferation	during	the	blood	stage,	
simultaneous inhibition of both results in a significant reduction in 
parasite growth. While our data support the concept of oligomeric 
protein	 interference	 assays	 for	 cytosolic	 proteins,	 in	 principle	 the	
use of the native targeting sequence will also allow the approach to 
be	used	for	proteins	present	in	other	cellular	compartments	(mito-
chondrial,	apicoplast,	membrane	inserted,	etc.).
A	 number	 of	 recent	 manuscripts	 have	 focused	 on	 elucidating	
the	role	of	the	mitochondria	of	the	malarial	parasite	(Ke	et	al.,	2015;	
Nixon	et	al.,	2013).	Amongst	the	pathways	supported	by	the	mito-
chondria are those involved in the biosynthesis of aspartate. While 
aspartate	is	essential	in	the	formation	of	new	proteins,	it	is	also	a	key	






cell protein does not sufficiently suit the need of P. falciparum for 
the rapid proliferation within blood stage as demonstrated by the 
presented	 growth	 experiments	 of	 blood-stage	 cultures	 in	 aspar-
tate-limited	media.	Thus,	aspartate	biosynthesis	or	uptake	is	highly	
likely to be a key element in supporting the rapid proliferation of 
P. falciparum in human red blood cells. It has long been known that 
aspartate is the least common of all the amino acids available within 
F I G U R E  8  Transcription	profile	of	AspAT-Y68A/R257A	+	MDH-
V190W	transgenic	cell	line.	The	analysis	was	done	via	the	2−ΔΔCt 
method in triplicates and three independent experiments. The PCR 
was	carried	out	with	specific	primers	for	both	proteins.	Aldolase	
was used as endogenous control. The values presented in the figure 
represent the relative amount of transcripts with the corresponding 
standard deviation
F I G U R E  9   Protein expression of the 





via western blot. Control experiments 
with 3D7 parasites as well as the parasites 
transfected	with	MOCK	plasmids	are	
shown	in	Lanes	1,	4,	and	6
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the	 human	 serum,	with	 recent	measurements	 suggesting	 that	 the	
concentration	of	L-aspartate	in	human	sera	is	<20	µM	(Psychogios	et	
al.,	2011).	This	strongly	suggests	that	biosynthetic	pathways	would	
be the main source of the aspartate required by P. falciparum in the 
human	host	(Figure	11).
The	 significant	 drop	 in	 proliferation	 upon	 oligomeric-based	
inhibition of both PfMDH	and	PfAspAT	 in	 aspartate-limited	 cell	
culture media suggest that aspartate biosynthesis in the malar-
ial parasite depends upon the function of both of these enzymes 
and validates this metabolic pathway as drug target in P. falci‐




calculations have predicted PfMDH	 as	 an	 essential	 enzyme.	 In	





MIS approach suggested PfAspAT	 as	 non-essential,	 corroborat-
ing	with	our	data,	which	shows	no	effect	on	the	knock-down	of	
PfAspAT	 alone	 although	 an	 intra-cellular	 simultaneous	 over-ex-
pression of PfAspAT	and	PfMDH	mutated	proteins	clearly	causing	
a severe growth defect. While the simultaneous inhibition of two 
enzymes may be highly challenging for the development of novel 
antimalarials,	our	data	strongly	suggest	 that	 future	drug	targets	
to treat malaria infection may be found within downstream com-
ponents	of	the	aspartate	metabolism	pathway	(Figure	11).	Taken	
together,	 our	 data	 also	 show	 that	 oligomeric	 surfaces	 offer	 a	
highly promising opportunity to specifically influence protein be-
havior in vivo and offer a novel avenue in the validation of path-
ways	for	downstream	drug	development,	particularly	in	the	field	
of infectious diseases.
4  | MATERIAL AND METHODS
4.1 | Expression and purification of recombinant 
PfAspAT
The purification of PfAspAT	has	been	previously	reported	(Jain	et	al.,	
2010).	Wild-type	PfAspAT	open	reading	frame	(ORF)	was	cloned	into	
pASK-IBA3	 expression	 plasmid	 with	 additional	 C-terminal	 His6-tag	
to	facilitate	purification	via	Ni-NTA	chromatography.	The	generated	
pASK-IBA3-PfAspAT	plasmid	was	transformed	into	the	commercially	





F I G U R E  11   Importance of the aspartate metabolism in 
Plasmodium falciparum. Our experiments showed that inhibition of 
the	de-novo	aspartate	biosynthesis	via	PfMDH	and	PfAspAT	is	a	
viable target for future antimalarial drug design








The single mutants PfAspAT-Y68A	 and	 PfAspAT-R257A,	 and	 the	
double mutant PfAspAT-Y68A/R257A	 were	 generated	 via	 site-di-
rected mutagenesis using specific oligonucleotides containing the 
altered	 codons	 (Appendix	1)	 and	 the	pASK-IBA3-PfAspAT	plasmid	
(Jain	 et	 al.,	 2010)	 as	 a	 template.	 All	 constructs	 were	 verified	 by	
Sanger sequencing.
4.3 | Determination of oligomeric state
The analysis of the oligomeric state of recombinant WT PfAspAT	
and mutants was performed according to the previously de-
scribed	 protocol	 (Wrenger	 et	 al.,	 2011).	 Briefly,	 PfAspAT-WT,	








4.4 | Recombinant co‐expression and co‐




Strep-tag.	 The	 His6-tagged	 PfAspAT-Y68A/R257A	 double	 mutant	
was	sub-cloned	into	pACYC184	vector	(NEB)	containing	the	expres-
sion	cassette	of	pJC40	to	allow	co-expression	of	the	WT	and	mutant	
version in E. coli.	 The	 co-expression	 of	 Strep-tagged	 PfAspAT-WT	
and	 His6-tagged	 PfAspAT-Y68A/R257A	 was	 performed	 using	 co-






4.5 | In vitro activity assays
The specific activity of the double mutant of PfAspAT-Y68A/R257A	
was measured following the same procedure as previously re-
ported	(Wrenger	et	al.,	2011).	The	effect	of	incorporation	of	mutant	
His6-tagged	 PfAspAT-Y68A/R257A	 into	 the	 native	 Strep-tagged	
wild-type	assembly	was	also	analyzed	using	the	samples	of	the	co-
expression	experiments	(described	above).
4.6 | Cloning and transfection of PfMDH 
V190W and PfAspAT Y68A, R257A
In	order	to	obtain	transgenic	parasites,	the	ORFs	of	WT-PfAspAT	
and PfAspAT-Y68A/R257A	 were	 amplified	 via	 PCR	 using	 se-
quence-specific	 primers	 (Appendix	 1)	 and	 subsequently	 cloned	
into	pARL	1a-	with	 the	hDHFR	 (human	dihydrofolate	 reductase)	
resistance	cassette	(Wrenger	&	Müller,	2004).	The	resulting	plas-
mids	encoded	for	the	full-length	WT-PfAspAT	and	PfAspAT-Y68A/
R257A	mutant	 with	 an	 additional	 C-terminal	 Strep-tag	 followed	
by	 the	 stop-codon	 before	 the	 GFP	 gene	 encoded	 on	 pARL	 1a-.	
Similarly,	WT-PfMDH	and	the	PfMDH-V190W	mutant	with	C-ter-
minal	His6-tag	(cloning	procedure	described	in	(Lunev	et	al.,	2018))	




tion	 effects,	 two	 MOCK	 plasmids	 were	 generated	 (pARL-MOCK-
hDHFR,	pARL-MOCK-BSD)	as	described	in	(Knöckel	et	al.,	2012).	All	
constructs	were	confirmed	by	automatic	sequencing	(Sanger)	before	
transfection into P. falciparum. The transfection of the resulting con-
structs	 pARL-PfAspAT-Y68A/R257A-Strep-hDHFR,	 pARL-PfMDH-
V190W-his-BSD,	 pARL-MOCK-hDHFR	 and	 pARL-MOCK-BSD	was	
performed into ring stage P. falciparum	3D7	as	described	in	(Knöckel	
et	al.,	2012;	Müller	et	al.,	2010).	The	co-transfected	cell	lines	were	
generated using the stabilized parasites previously transfected with 
pARL-PfAspAT-Y68A/R257A-Strep-hDHFR	or	pARL-MOCK-hDHFR,	
which	 were	 then	 electroporated	 with	 pARL-PfMDH-V190W-his-
BSD	or	 pARL-MOCK-BSD	plasmids,	 respectively.	 The	 selection	 of	
transgenic	 parasites	was	 performed	 using	 5	nM	 of	WR99210	 and	
1 μg/ml Blasticidin S. Transfected parasites were maintained in con-
tinuous culture using the conditions of Trager and Jensen modified 
as	described	in	(Das	et	al.,	2005).
4.7 | qRT and western blot
An	asynchronous	culture	of	 transgenic	3D7	parasites	was	 isolated	
via	 saponin	 lysis.	 The	 total	 RNA	of	 these	 parasites	was	 extracted	
using	TRIZOL	 following	 the	manufacturer’s	 instruction.	The	cDNA	
synthesis	was	 performed	 as	 described	 in	 (Butzloff,	 2013;	Chan	 et	
al.,	2013;	Knöckel	et	al.,	2012;	Müller	et	al.,	2010).	The	quantitative	
real-time	PCR	was	performed	using	 specific	primers	 (Appendix	1),	
that	identify	products	from	150–190	bp.	Briefly,	2	μl of each primer 
(5	pmol/μl)	were	 used	 together	with	 9	μl	 of	 2.5×	Real	Master	Mix	
SYBR	(20×;	5Prime),	6	μl	RNAse-free	dH2O and 1 μl	cDNA	(50	ng/
μl).	The	reaction	was	performed	in	a	thermocycler	(Corbett	Cycler)	
with	 the	 following	 program:	 2	min	 95°C	 followed	 by	 35	 cycles	 of	
95°C	for	15	s,	49°C	for	20	s	and	69°C	for	20	s,	and	a	final	step	of	
95°C	for	2	min.	Normalization	and	calibration	were	performed	using	
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the	 aldolase	 gene	 (Salanti	 et	 al.,	 2003)	 and	 the	 respective	MOCK	
cell	 line	 like	 (Chan	et	al.,	2013).	The	data	were	analyzed	using	 the	
Corbett	Rotor-Gene	6.1.81	software	and	the	2−ΔΔCt	method	 (Livak	
&	Schmittgen,	2001).








anti-mouse	 HRP-labeled	 antibody	 (1:10,000	 dilution;	 Pierce)	 and	
visualized	on	X-ray	films	using	the	SuperSignal	West	Pico	detection	
system	(Thermo	Scientific).
4.8 | Activity assays from parasites lysate










The specific activity of PfAspAT	was	measured	with	the	Aspartate	
Aminotransferase	(AST)	Activity	Assay	Kit	(Sigma	Aldrich).	The	reac-
tion	was	carried	out	at	37°C	in	a	final	volume	of	100	µl,	according	to	




In	 order	 to	 analyze	 the	 long-term	 influence	 of	 the	 overexpressing	
cell	lines	pARL-PfAspAT-Y68A/R257A-Strep-hDHFR,	pARL-PfMDH-
V190W-his-BSD	 and	 the	 double	 transgenic	 cell	 line	 pARL-PfAs-
pAT-Y68A/R257A-strep-hDHFR	+	pARL-PfMDH-V190W-his-BSD	
in	 comparison	with	 their	 respective	MOCK	 line,	 parasites	 growth	
was monitored over several days. The parasites were synchronized 
using	sorbitol	and	a	starting	parasitaemia	of	1%	of	ring-stage	iRBC	
(infected	red	blood	cells)	was	adjusted.	Giemsa-stained	thin	smears	
were analyzed daily and the parasitaemia was determined by light 
microscopy in percentage of iRBC to total RBC. Cultures with more 
than 8% of iRBC were diluted and cumulative parasitaemias were 
calculated	as	described	in	(Knöckel	et	al.,	2012).	Triple	repetition	of	
the proliferation assay was performed and the growth curves were 
generated	 with	 GraphPad	 Prism	 4.0.	 The	 slope	 of	 the	 respective	
curves	was	 calculated	 through	 an	 exponential	 equation	 (Müller	 et	
al.,	2009).
4.10 | Localization of PfMDH
The	ORF	 of	 PfMDH-WT	with	 no	 stop-codon	 at	 C-terminus	 was	
amplified	 by	 PCR	 and	 subsequently	 cloned	 into	 pARL	 1a-	 using	
KpnI/AvrII	restriction	enzymes	(Appendix	1).	The	resulting	plasmid	
encoded	for	the	wild-type	PfMDH	fused	in	front	of	the	GFP	gene	
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Mutations sites are underlined
Primer Sequence
PfAspAT	cloning	for	recombinant	expression	(pASK-IBA3,	His6-tag)
IBA3-AspAT-s	(BsaI,	His6) 5′-GCGCGCGGTCTCCAATGGATAAGTTATTAAGCAGCTTAG-3′
IBA3-AspAT-as	(BsaI,	His6) 5′-GCGCGCGGTCTCAGCGCTTTAATGATGATGATGATGATGGCCCTGAAA 
ATAAAGATTCTCTATTTGACTTAGCGAAAGACAAATTTTGTCGG-3′
PfAspAT	cloning	for	recombinant	expression	(pASK-IBA3,	Strep-tag)
IBA3-AspAT-s	(BsaI,	Strep) 5′-GCGCGGTCTCCAATGGATAAGTTATTAAGCAGCTTAG-3′
IBA3-AspAT-as	(BsaI,	Strep) 5′-GCGCGGTCTCTGCGCTTATTTGACTTAGCGAAAGAC-3′
PfAspAT	Site-directed	mutagenesis	primers	(pASK-IBA3)
AspAT-R257A-s 5′-ATGTCGCTTTATGGAGAAGCAGCAGGTGCTCTTCATATTG-3′
AspAT-R257A-as 5′-CAATATGAAGAGCACCTGCTGCTTCTCCATAAAGCGACAT-3′
AspAT-Y68A-s 5′-GAAAATTATAAAGAGAAACCAGCATTGTTAGGTAACGGTACAGAA-3′
AspAT-Y68A-as 5′-TTCTGTACCGTTACCTAACAATGCTGGTTTCTCTTTATAATTTTC-3′
PfAspAT	sub-cloning	primers	for	recombinant	co-expression	in	E. coli	(pACYC184)
pACYC184-AspT-s	(NdeI) 5′-AGAGCATATGGATAAGTTATTAAGCAGCTTAG-3′
pACYC184-AspT-as	(XmaI) 5′-ATATCCCGGGTCATATTTGACTTAGCGAAAGA-3′
PfAspAT	double	mutant	sub-cloning	primers	for	in	vivo	overexpression	(pARL	1a-)
pARL-AspAT-s	(KpnI) 5′-GAGAGGTACCATGGATAAGTTATTAAGCAGCTTAG-3′
pARL-AspAT-Strep-as	(XhoI) 5′-GCGCCTCGAGTTATTATTTTTCGAACTGCGGGTGGC-3′
PfAspAT	qPCR	primers
qPCR-AspAT-s 5′-CGCCTTTTCGGTATGTCAATCC-3′
qPCR-AspAT-as 5′-AGTTGGCATAGAATACGATTCGT-3′
PfMDH	double	mutant	sub-cloning	primers	for	in	vivo	overexpression	(pARL	1a-)
pARL-MDH-s	(SmaI) 5′-GAGACCCGGGATGGTACCAGCTCGAGCCTAGGATGACTAAAATT	
GCCTTAATAGG-3′
pARL-MDH-His-as	(XhoI) 5′-GAGACTCGAGTTATTAATGATGATGATGATGATG-3′
PfMDH	qPCR	primers
qPCR-MDH-s 5′-CCCAGCTGCTGCTATTACAA-3′
qPCR-MDH-as 5′-CTGGATGTGCCCCCTTATTA-3′
PfAldolase	qPCR	control	gene
qPCR-PfAldolase-s 5′-TGTACCACCAGCCTTACCAG-3′
qPCR-PfAldolase-as 5′-TTCCTTGCCATGTGTTCAAT-3′
